Clinical trials: Anti-Retroviral Agents
HIV Infections
The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy
The purpose of this study is to see how HIV-positive patients who are taking anti-HIV drugs and have a viral load (level of HIV in the blood) of 1,500 copies/ml or more respond to GM-CSF (granulocyte-macrophage colony-stimulating…
- Trial name
- NCT00000850
- Testing
- Indinavir sulfate, Sargramostim
- Where
- 39 sites in United States
- Volunteers
- 108 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study of Two Anti-HIV Drug Combinations
The purpose of this study is to compare the safety and effectiveness of taking lamivudine (3TC) plus zidovudine (ZDV) plus a protease inhibitor (PI) with taking the 3TC/ZDV combination tablet (Combivir) plus a PI.
- Trial name
- NCT00002203
- Testing
- Lamivudine/Zidovudine, Lamivudine, Zidovudine
- Where
- 7 sites in United States, Puerto Rico
- Sponsor
- Glaxo Wellcome
HIV Infections, Gonorrhea
Cellulose Sulfate (CS) Gel and HIV in Nigeria
This is a Phase 3, multi-center, randomized, placebo-controlled trial to determine the effectiveness and safety of the 6% cellulose sulfate (CS) vaginal gel for the prevention of HIV infection.
- Conditions
- HIV Infections, Gonorrhea, Chlamydia Infections
- Trial name
- NCT00120770
- Testing
- Cellulose Sulfate Vaginal Gel (Microbicide)
- Where
- 2 sites in Nigeria
- Volunteers
- 2,160 people, healthy volunteers welcome
- Sponsor
- FHI 360
HIV Infection
Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to Antiretrovirals (ARVs)
The purpose of this study is to evaluate, in patients in at least the second protease inhibitor (PI) line, the virological failures under Kaletra® and their consequences on protease and reverse transcriptase genotypes
- Trial name
- EOLE (NCT01103596)
- Where
- 19 sites in France
- Volunteers
- 94 people
- Sponsor
- Abbott
HIV Infections
A Study to Evaluate the Effect of Anti-HIV Therapy on Lean Tissue (Muscle) in HIV-Positive Patients
The purpose of this study is to determine whether HIV-positive patients with extremely low viral loads (level of HIV in the blood) have a greater gain in lean tissue during anti-HIV (antiretroviral) therapy than patients with…
- Trial name
- NCT00000890
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
To assess the efficacy of enfuvirtide (Fuzeon) added to HAART compared to treatment with HAART alone in achieving and maintaining viral load suppression.
- Trial name
- INTENSE (NCT00487188)
- Testing
- Enfuvirtide, Highly active antiretroviral treatment (HAART)
- Where
- 39 sites in United States, Canada and 8 more
- Volunteers
- 47 people
- Sponsor
- Hoffmann-La Roche
HIV Infection
Pharmacokinetics of Antiretroviral Agents in HIV-1 Infected Pregnant Women
This study will determine if blood levels of anti-HIV drugs in pregnant women change at different stages of pregnancy and if these changes require dosage adjustments in order to maintain adequate drug levels during pregnancy.
- Trial name
- NCT00006320
- Testing
- determine blood levels of anti-HIV drugs
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, PCP
Antiretroviral Drug Interaction Study in Volunteers With HIV
Background: People who are infected with the human immunodeficiency virus (HIV) are at risk of getting certain diseases. Two of these diseases are a type of pneumonia known as PCP and a brain infection called toxoplasmosis.
- Conditions
- HIV, PCP, Toxoplasmosis
- Trial name
- NCT01479361
- Testing
- Atovaquone 750 mg twice daily, Atovaquone 1500 mg twice daily
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Cardiovascular Diseases, Platelet Aggregation, Spontaneous
Platelet Function on Abacavir and Tenofovir
This is a small observational study aimed at observing differences in platelet function in HIV patients on abacavir versus tenofovir based anti-HIV drugs.
- Conditions
- Cardiovascular Diseases, Platelet Aggregation, Spontaneous, HIV/AIDS
- Trial name
- NCT03081572
- Testing
- Platelet aggregation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, Los Angeles
HIV Infections
TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.
The purpose of this study is to provide early access to TMC114 (a protease inhibitor) for HIV-1 infected patients with limited or no treatment options, who have failed multiple antiretroviral (ARV) regimens, and to evaluate the…
- Trial name
- NCT00245739
- Testing
- TMC-114
- Where
- 394 sites in United States, Belgium and 20 more
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV-1 Virologic Response
HIV Treatment Retention Interventions for Women Living With HIV (Siyaphambili Study)
The Siyaphambili Study is a sequential multistage adaptive randomized trial (SMART) to compare the effectiveness and durability of two behavioral interventions on the HIV-1 virologic response among female sex workers (FSW) living…
- Trial name
- NCT03500172
- Testing
- DTP, ICM
- Where
- South Africa
- Volunteers
- 1,391 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV-1, HIV Infections
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed dose combination (FDC) plus darunavir (DRV) relative to current antiretroviral…
- Conditions
- HIV-1, HIV Infections, Acquired Immunodeficiency Syndrome
- Trial name
- NCT01968551
- Testing
- E/C/F/TAF, DRV, Baseline DRV- containing ARV regimen
- Where
- 62 sites in United States, Canada
- Volunteers
- 158 people
- Sponsor
- Gilead Sciences
HIV Infections
Intermittent Therapy in HIV-1 Infected Patients With Successful Viral Suppression Under Highly Active Antiretroviral Therapy (HAART)
Although lifelong continuous therapy with HAART remains the standard of care of HIV infection, allowing to achieve undetectable plasma viral RNA, restore CD4 cell count and provide substantial decline in HIV-related morbidity and…
- Trial name
- NCT00122551
- Testing
- Intermittent antiretroviral therapy
- Where
- 2 sites in France
- Volunteers
- 400 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infections
A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients
The purpose of this study is to evaluate the effects of a 3-drug anti-HIV regimen, amprenavir (APV) plus abacavir (ABC) plus lamivudine (3TC), on the way carbohydrates (sugars) and fats are metabolized (processed by the body) in…
- Trial name
- NCT00002245
- Testing
- Abacavir sulfate, Amprenavir, Lamivudine
- Where
- United States
- Sponsor
- Glaxo Wellcome
HIV Infections
Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People
The purpose of this study is to determine the effect of short cycles of recombinant interleukin-2 (also known as rIL-2 or aldesleukin) given with or without anti-HIV drugs in HIV infected patients.
- Trial name
- STALWART (NCT00110812)
- Testing
- IL-2
- Where
- 36 sites in United States, Argentina and 9 more
- Volunteers
- 267 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era
SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data.
- Trial name
- SCOPE (NCT00187512)
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- University of California, San Francisco
HIV Infections
Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy
The purpose of this study is to determine the safety of two recombinant HIV vaccines in HIV infected young adults on stable anti-HIV therapy.
- Trial name
- NCT00107549
- Testing
- rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)]), rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Antiretroviral Treatment
Nevirapine / Lamivudine for HIV Maintenance Therapy
The standard treatment for HIV infection involves taking a combination of three HIV drugs. The main reason for using multiple substances is to prevent resistance from developing rapidly when only one or two drugs are used.
- Conditions
- HIV Infection, Antiretroviral Treatment, Maintenance Therapy
- Trial name
- NCT07014189
- Testing
- Neviparine (NVP)/ Lamivudine (3TC)
- Where
- Switzerland
- Volunteers
- 201 people
- Sponsor
- Cantonal Hospital of St. Gallen
HIV Infections
The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year
To determine, in HIV-infected patients, whether switching to a new soft gelatin capsule formulation of saquinavir or to indinavir following prolonged use of the original hard capsule formulation of saquinavir results in an acute…
- Trial name
- NCT00000848
- Testing
- Indinavir sulfate, Saquinavir
- Where
- 16 sites in United States
- Volunteers
- 144 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy
PRIMARY: To examine the effect of aldesleukin ( IL-2 ) on viral activity in the blood. To determine the safety of low-dose IL-2 in combination with antiretroviral therapy versus antiretroviral therapy alone.
- Trial name
- NCT00000820
- Testing
- Aldesleukin
- Where
- 10 sites in United States
- Volunteers
- 104 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.